Moshe Lapidot, M.D.

About Dr. Lapidot

Thoracic surgeon Dr. Moshe Lapidot is an experienced thoracic surgeon at Brigham and Women’s Hospital and a surgical instructor at Harvard Medical School. 

Lapidot graduated from Technion-Israel Institute of Technology in 2006 with his doctorate in medicine. He went on to complete his thoracic surgery fellowship at Harvard Medical School in 2018. Since then, he’s been focusing on research that could lead to new treatments for mesothelioma. 

“I believe there is still much to learn about how mesothelioma grows and develops in the body,” said Lapidot. “But every day provides hope that a new piece of information will eventually lead to a cure.”

In 2021, Dr. Lapidot and his research team published their work on a potential new mesothelioma immunotherapy target called STAT3. By inhibiting the STAT3 transcription factor, immune cells can more readily identify and eliminate mesothelioma cancer. 

“This target for mesothelioma immunotherapy has great potential,” said Lapidot. “Our data from this study suggested that STAT3 inhibitors could play a vital role combined with immune checkpoint inhibitors or chemotherapy.”

Lapidot’s research has also uncovered a potential new therapy called heparanase inhibitors. These drugs inhibit blood vessel growth on tumors, restricting their blood supply and drastically limiting their ability to grow and spread. 

“The results strongly encourage further testing, and I’m optimistic that these therapies could become a new standard one day,” Lapidot said.

Dr. Lapidot’s Role as Medical Reviewer on Asbestos.com

Lapidot has many years of experience in mesothelioma surgery and research. His clinical research work paves the way for new treatments, making him an ideal medical reviewer of mesothelioma information.

In his review process he ensures that content on Asbestos.com meets the highest medical and scientific standards for accuracy regarding the latest treatment methods for asbestos-related diseases.